Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12118230 | 0.93 | PAOX (0.38) | PAOXACHEALDH1A1MAPT | |
| SCHEMBL12287350 | 0.93 | PAOX (0.38) | PAOXACHEALDH1A1MAPT | |
| SCHEMBL12287701 | 0.93 | PAOX (0.38) | PAOXACHEALDH1A1MAPT | |
| SCHEMBL1650867 | 0.83 | TBXAS1 (0.41) | ALDH1A1MAPT | |
| SCHEMBL12118190 | 0.82 | CXCR2 (0.31) | — | |
| SCHEMBL13880497 | 0.81 | CASP2 (0.36) | PAOX | |
| SCHEMBL10435516 | 0.78 | TBXAS1 (0.47) | ALDH1A1MAPT | |
| SCHEMBL13880437 | 0.77 | KDM4E (0.44) | PAOX | |
| SCHEMBL1639942 | 0.77 | ALDH1A1 (0.41) | ALDH1A1 | |
| SCHEMBL12641022 | 0.77 | PPARG (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9480753-B2 | FGF21 derivatives with albumin binder A-B-C-D-E- and their use | NOVO NORDISK A/S (DK) | 2016-11-01 | — | — | US | disclosed |
| US-9464048-B2 | 5-oxo-ETE receptor antagonist compounds | FLORIDA INSTITUTE OF TECHNOLOGY (US) | 2016-10-11 | — | — | US | disclosed |
| US-9464048-B2 | 5-oxo-ETE receptor antagonist compounds | FLORIDA INSTITUTE OF TECHNOLOGY (US) | 2016-10-11 | — | — | US | disclosed |
| US-20160289283-A1 | SELECTIVE PYY COMPOUNDS AND USES THEREOF | NOVO NORDISK (DK) | 2016-10-06 | — | — | US | disclosed |
| WO-2016066818-A1 | COMPOSITIONS AND PEPTIDES HAVING DUAL GLP-1R AND GLP-2R AGONIST ACTIVITY | GUBRA APS (DK) | 2016-05-06 | — | — | WO | disclosed |
| US-9085637-B2 | Selective PYY compounds and uses thereof | NOVO NORDISK A/S (DK) | 2015-07-21 | — | — | US | disclosed |
| US-20150152150-A1 | Selective PYY compounds and uses thereof | NOVO NORDISK A/S (DK) | 2015-06-04 | — | — | US | disclosed |
| EP-2842965-A1 | Neuromedin U analogs comprising serum albumin binding amino acid residue | Gubra ApS (DK) | 2015-03-04 | — | — | EP | disclosed |
| US-20140323535-A1 | 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2014-10-30 | — | — | US | disclosed |
| US-20140323535-A1 | 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2014-10-30 | — | — | US | disclosed |
| US-8809382-B2 | 5-oxo-ETE receptor antagonist compounds | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2014-08-19 | — | — | US | disclosed |
| US-8809382-B2 | 5-oxo-ETE receptor antagonist compounds | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2014-08-19 | — | — | US | disclosed |
| US-20120122942-A1 | 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS | FLORIDA INSTITUTE OF TECHNOLOGY | 2012-05-17 | — | — | US | disclosed |
| US-20120122942-A1 | 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS | FLORIDA INSTITUTE OF TECHNOLOGY | 2012-05-17 | — | — | US | disclosed |
| WO-2010127452-A1 | 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2010-11-11 | — | — | WO | disclosed |
| US-20100216715-A1 | FGF21 Derivatives With Albumin Binder A-B-C-D-E- And Their Use | NOVO NORDISK A/S (DK) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160289283-A1 | SELECTIVE PYY COMPOUNDS AND USES THEREOF | NPY1R, NPY5R, NPY2R | PAOX 686/4885ACHE 4134/4885ALDH1A1 4809/4885 |
| US-20120122942-A1 | 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS | OXER1, PTGIR, EDNRA | PAOX 800/4885ACHE 2332/4885ALDH1A1 1506/4885 |
| US-20100216715-A1 | FGF21 Derivatives With Albumin Binder A-B-C-D-E- And Their Use | FABP1, FABP4, FGFR1 | PAOX 756/4885ACHE 4730/4885ALDH1A1 207/4885 |
| US-20150152150-A1 | Selective PYY compounds and uses thereof | NPY1R, NPY5R, NPY2R | PAOX 686/4885ACHE 4134/4885ALDH1A1 4809/4885 |
| US-20140323535-A1 | 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS | OXER1, PTGIR, EDNRA | PAOX 800/4885ACHE 2332/4885ALDH1A1 1506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.